●founderWorth watching because Prometheus is staking out physical engineering and drug design simultaneously, which could crowd out startups in robotics, CAD automation, and computational biology.
●investorA $41B valuation for a pre-product physical AI company sets a new ceiling for the category and signals massive capital concentration in physical-world automation.
●healthDrug design is an explicit target use case, making this a direct competitive signal for biotech AI startups and computational drug discovery platforms.